BGM and CGM Market

The BGM and CGM Market Report highlights a rapidly expanding global diabetes monitoring ecosystem with over 537 million adults living with diabetes in 2021, expected to exceed 640 million by 2030. More than 75% of diabetes patients require regular glucose monitoring, driving demand for both blood glucose meters (BGM) and continuous glucose monitoring (CGM) systems. CGM adoption has increased significantly, with over 8 million active users globally, while BGM devices still account for approximately 65%–70% of total device usage due to affordability. The BGM and CGM Market Analysis shows that more than 1.2 billion test strips are used annually, indicating strong consumable demand.

The USA BGM and CGM Market is one of the most advanced, with over 37 million people diagnosed with diabetes and approximately 96 million adults classified as prediabetic. Around 30%–35% of insulin-dependent patients in the U.S. use CGM systems, compared to less than 10% in 2015, showing rapid adoption. Medicare expanded CGM coverage in 2023, increasing eligible users by over 2 million individuals. The BGM segment still dominates in volume, with over 70 million glucose tests conducted daily across the country. The BGM and CGM Industry Report indicates that more than 85% of endocrinologists in the U.S. recommend CGM for type 1 diabetes management.

Market Latest Trends

The BGM and CGM Market Trends indicate a strong shift toward real-time monitoring, with CGM devices capturing glucose readings every 1–5 minutes, resulting in over 288 readings per day per patient. Wearable CGM sensors now last up to 14–15 days, compared to earlier versions lasting only 3–5 days, improving patient compliance by over 40%. Smartphone integration has reached over 90% compatibility, enabling remote monitoring for more than 5 million users globally.

The BGM and CGM Market Insights also show the integration of AI-based predictive analytics, with systems capable of forecasting glucose fluctuations up to 30–60 minutes in advance. Flash glucose monitoring systems account for approximately 25%–30% of CGM usage, especially in Europe and Asia-Pacific regions. Additionally, non-invasive monitoring technologies are under development, with over 50 clinical trials ongoing globally as of 2024.

Another major trend in the BGM and CGM Industry Analysis is the expansion of pediatric adoption, with CGM usage among children under 18 years increasing by more than 60% between 2020 and 2024. Subscription-based models for sensors and strips are also rising, with over 20% of users opting for monthly supply plans. The BGM and CGM Market Forecast suggests continued innovation in sensor miniaturization, with device sizes reduced by over 35% in the last decade.

Market Dynamics

DRIVER

Increasing Prevalence of Diabetes Globally

The primary driver in the BGM and CGM Market Growth is the rising prevalence of diabetes, with more than 537 million adults affected globally in 2021, projected to increase by over 100 million cases within the next decade. Type 2 diabetes accounts for approximately 90%–95% of all cases, largely driven by urbanization, sedentary lifestyles, and obesity rates exceeding 650 million globally. Frequent monitoring is essential, with insulin-dependent patients testing glucose levels up to 4–10 times daily, supporting strong demand for both BGM and CGM devices. Additionally, gestational diabetes affects approximately 16% of pregnancies worldwide, creating additional monitoring needs. Government initiatives in over 80 countries promoting early diagnosis and self-monitoring further accelerate device adoption.

RESTRAINT

High Cost of CGM Devices and Limited Accessibility

A major restraint in the BGM and CGM Market Outlook is the high cost associated with CGM systems, where sensors need replacement every 7–14 days, leading to annual usage of over 26–52 sensors per patient. In many low- and middle-income countries, less than 20% of patients have access to advanced monitoring devices, limiting penetration. BGM devices remain more affordable, with test strips costing significantly less per use, contributing to their continued dominance in volume. Insurance coverage disparities affect over 40% of global patients, restricting CGM adoption. Additionally, device calibration requirements and sensor accuracy concerns, especially in early-stage models, have impacted user trust among approximately 15%–20% of patients.

OPPORTUNITY

Expansion of Digital Health and Remote Monitoring

The BGM and CGM Market Opportunities are strongly driven by digital health integration, with over 60% of CGM devices now connected to mobile apps and cloud platforms. Telehealth usage increased by more than 300% between 2020 and 2023, enabling remote glucose monitoring for over 10 million patients globally. Integration with insulin pumps and automated insulin delivery systems has improved glycemic control by reducing hypoglycemia events by up to 40%. Emerging markets, including India and China, represent over 40% of the global diabetic population, offering significant untapped potential. Government-led digital health programs in more than 25 countries are further supporting remote monitoring adoption.

CHALLENGES

Data Accuracy and Device Compliance Issues

One of the key challenges in the BGM and CGM Market Research Report is maintaining accuracy across varying physiological conditions. CGM devices typically have a mean absolute relative difference (MARD) of around 8%–12%, which may affect clinical decision-making. BGM devices require proper calibration and user technique, with incorrect usage reported in approximately 20%–30% of cases. Device wearability issues, including skin irritation, affect nearly 10%–15% of CGM users. Additionally, data overload from continuous monitoring, generating over 288 data points per day, creates challenges in interpretation for both patients and healthcare providers.

SWOT Analysis

Strengths

• Over 537 million global diabetes patients, ensuring strong demand

• CGM devices provide 288 readings per day, enhancing disease management

• BGM devices account for 65%–70% usage share, ensuring accessibility

• Sensor lifespan improvements from 5 days to 14 days, boosting compliance

Weaknesses

• CGM adoption limited to 30%–35% in developed regions

• High replacement frequency of 26–52 sensors annually

• Accuracy variability of 8%–12% MARD

• User error in BGM usage reported in 20%–30% of cases

Opportunities

• Over 10 million users adopting remote monitoring globally

• Emerging markets account for 40%+ diabetic population

• AI integration predicting glucose levels 30–60 minutes ahead

• Pediatric adoption increased by 60% in 4 years

Threats

• Limited access in regions with less than 20% device penetration

• Skin-related issues impacting 10%–15% users

• Regulatory compliance requirements across 100+ countries

• Competition from non-invasive monitoring technologies under 50+ trials

Segmentation Analysis

The BGM and CGM Market Segmentation is primarily divided by type and application. CGM systems are gaining traction due to real-time monitoring, while BGM devices remain dominant due to affordability and widespread availability. Applications are divided into hospital and household settings, with household usage accounting for over 60%–65% of total demand, driven by home-based care trends.

By Type

• Continuous Glucose Monitoring (CGM)

The CGM segment accounts for approximately 30%–35% of the total market share, with over 8 million users globally. CGM devices provide continuous readings every 1–5 minutes, generating up to 288 readings daily. Sensor lifespan has improved to 14–15 days, reducing replacement frequency. CGM adoption among type 1 diabetes patients exceeds 50% in developed markets, while type 2 adoption is growing steadily. Integration with smartphones is above 90%, enabling remote tracking. The BGM and CGM Market Insights highlight that CGM reduces hypoglycemic events by up to 40%, improving patient outcomes significantly.

• Blood Glucose Meter (BGM)

The BGM segment holds around 65%–70% market share, supported by affordability and accessibility. Over 1.2 billion test strips are used annually, indicating high usage frequency. BGM devices are widely used in developing regions, where over 80% of diabetic patients rely on fingerstick testing. Daily testing frequency ranges from 2 to 10 times, depending on disease severity. The devices are compact, with over 500 million units sold globally. Despite the rise of CGM, BGM remains essential for calibration and backup, ensuring continued demand in the BGM and CGM Market Report.

By Application

• Hospital

Hospital applications account for approximately 35%–40% of the market, driven by critical care monitoring and inpatient diabetes management. Hospitals conduct over 50 million glucose tests daily worldwide, particularly in ICU settings. CGM adoption in hospitals has increased by 25% since 2020, enabling real-time monitoring for critically ill patients. Inpatient diabetes prevalence ranges from 20%–30%, necessitating continuous monitoring. Integration with electronic health records has improved data tracking efficiency by over 40%.

• Household

Household applications dominate with around 60%–65% market share, supported by the growing trend of home-based healthcare. Over 400 million patients globally perform self-monitoring, with an average of 3–5 tests daily. CGM usage in households has increased by more than 50% in the last 5 years, particularly among insulin-dependent patients. Remote monitoring solutions are used by over 10 million households, enabling real-time data sharing with healthcare providers. The BGM and CGM Market Outlook highlights strong growth in this segment due to convenience and cost savings.

Regional Analysis

The BGM and CGM Market Size shows North America leading with over 40% share, followed by Europe at 25%–30%, Asia-Pacific at 20%–25%, and Middle East & Africa at 5%–10%.

• North America

North America dominates the BGM and CGM Market Share with over 40% global share, supported by advanced healthcare infrastructure and high diabetes prevalence. The U.S. alone has over 37 million diabetic patients, with more than 1.5 million new cases diagnosed annually. CGM adoption exceeds 30% among insulin users, while BGM remains widely used with over 70 million daily tests. Insurance coverage expansion has increased CGM accessibility for over 2 million additional patients since 2023. Canada reports diabetes prevalence of approximately 11% among adults, further supporting demand.

• Europe

Europe accounts for approximately 25%–30% of the BGM and CGM Market, with over 60 million diabetes patients across the region. Countries such as Germany, the UK, and France lead adoption, with CGM penetration exceeding 25% in developed nations. Government reimbursement programs cover up to 80%–100% of device costs in certain countries, boosting adoption. Flash glucose monitoring is particularly popular, accounting for nearly 30% of CGM usage. The region conducts over 200 million glucose tests daily, indicating strong BGM demand.

• Asia-Pacific

Asia-Pacific holds around 20%–25% market share, with more than 250 million diabetic patients, representing the largest patient pool globally. China and India alone account for over 150 million cases combined. BGM devices dominate with over 80% usage share, due to affordability. CGM adoption is increasing, with user growth exceeding 40% in the past 5 years. Government initiatives in countries like Japan and Australia support early diagnosis, with screening programs covering over 70% of at-risk populations.

• Middle East & Africa

The Middle East & Africa region accounts for 5%–10% of the BGM and CGM Market, with approximately 70 million diabetes patients. Prevalence rates exceed 15% in several Gulf countries, among the highest globally. BGM devices dominate with over 85% market share, while CGM adoption remains below 15% due to cost barriers. Healthcare investments have increased by over 20% in the past decade, improving access to diagnostic tools. Awareness campaigns have reached over 30 million individuals, supporting early detection and monitoring.

Competitive Landscape

The BGM and CGM Market Competitive Landscape is highly consolidated, with the top 5 players controlling over 70% of the market share. CGM segment leadership is concentrated among 2–3 major companies, accounting for more than 60% of CGM device adoption globally. Product innovation cycles occur every 12–24 months, with continuous improvements in sensor accuracy and lifespan.

More than 100 companies operate globally, but only around 20 manufacturers have significant international presence. Strategic partnerships and acquisitions have increased by over 30% since 2020, enabling expansion into emerging markets. Companies invest heavily in R&D, with over 15% of operational budgets allocated to innovation. Distribution networks cover over 150 countries, ensuring wide accessibility of BGM and CGM devices.

List of Top BGM and CGM Companies

• Abbott Laboratories

• DexCom, Inc.

• Medtronic plc

• F. Hoffmann-La Roche Ltd

• Ascensia Diabetes Care Holdings AG

• B. Braun SE

• LifeScan (a Johnson & Johnson company)

• ARKRAY, Inc.

• Senseonics Holdings, Inc.

• Ypsomed AG

Top Two companies with the highest market share

• Abbott Laboratories – holds approximately 30%–35% share in CGM segment, with over 4 million global users

• DexCom, Inc. – accounts for around 25%–30% CGM market share, with devices used by over 2 million patients worldwide

Market Investment Outlook

The BGM and CGM Market Investment Outlook shows strong capital inflows, with over $5 billion invested globally in diabetes technology startups between 2020 and 2024. More than 150 investment deals have been recorded, focusing on sensor innovation and digital health integration. Venture capital funding in CGM technology increased by over 40% in the last 3 years.

Manufacturers are expanding production capacities, with over 20 new manufacturing facilities established globally since 2022. Investments in AI-based analytics platforms have grown by over 35%, enabling predictive glucose monitoring. Emerging markets are receiving increased attention, with over 25% of investments directed toward Asia-Pacific and Latin America.

New Product Development

The BGM and CGM Market Trends highlight continuous innovation, with over 50 new products launched between 2023 and 2025. Next-generation CGM sensors offer accuracy levels below 10% MARD, improving clinical reliability. Sensor wear time has increased to 15 days, while calibration-free devices now account for over 70% of new launches.

Non-invasive monitoring technologies are under development, with over 20 prototypes in clinical trials. Integration with wearable devices such as smartwatches has increased by over 60%, enhancing user convenience. Miniaturization has reduced device size by over 30%, improving comfort. Battery life improvements allow devices to operate continuously for over 10–14 days without recharge.

Recent Developments

• In 2023, a leading manufacturer launched a CGM sensor with 15-day wear duration, improving usage efficiency by over 25%.

• In 2024, Medicare expanded CGM coverage to include over 2 million additional patients, increasing accessibility significantly.

• In 2023, a new AI-powered CGM platform enabled glucose prediction up to 60 minutes in advance, enhancing patient safety.

• In 2025, a compact BGM device was introduced with testing time reduced to 5 seconds, improving user convenience.

• In 2024, integration of CGM with insulin pumps improved glycemic control, reducing hypoglycemia events by up to 40%.